REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 189 filers reported holding REATA PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 2.52 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $281,000 | -11.9% | 8,565 | -29.1% | 0.02% | -15.0% |
| Q4 2021 | $319,000 | -94.7% | 12,085 | -79.8% | 0.02% | -95.0% |
| Q3 2021 | $6,014,000 | +23.7% | 59,775 | +74.0% | 0.40% | +26.4% |
| Q2 2021 | $4,862,000 | +89.0% | 34,355 | +33.1% | 0.31% | +65.3% |
| Q1 2021 | $2,573,000 | -16.1% | 25,805 | +4.1% | 0.19% | -21.2% |
| Q4 2020 | $3,065,000 | +43.2% | 24,790 | +12.8% | 0.24% | +25.5% |
| Q3 2020 | $2,141,000 | -29.6% | 21,980 | +12.7% | 0.19% | -30.2% |
| Q2 2020 | $3,042,000 | +161.8% | 19,500 | +142.2% | 0.28% | +133.1% |
| Q1 2020 | $1,162,000 | -24.2% | 8,050 | +7.3% | 0.12% | +51.3% |
| Q4 2019 | $1,533,000 | +154.7% | 7,500 | 0.0% | 0.08% | +200.0% |
| Q3 2019 | $602,000 | -15.0% | 7,500 | 0.0% | 0.03% | -7.1% |
| Q2 2019 | $708,000 | +29.4% | 7,500 | +17.2% | 0.03% | +33.3% |
| Q1 2019 | $547,000 | +62.3% | 6,400 | +6.7% | 0.02% | +40.0% |
| Q4 2018 | $337,000 | – | 6,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $291,457,000 | 32.14% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 46,646 | $4,693,000 | 5.31% |
| Ikarian Capital, LLC | 471,400 | $47,423,000 | 3.34% |
| Duquesne Family Office | 695,033 | $69,927,000 | 2.27% |
| Camber Capital Management LP | 685,000 | $68,918,000 | 2.12% |
| LBJ Family Wealth Advisors, Ltd. | 30,359 | $3,054,000 | 1.82% |
| MADDEN SECURITIES Corp | 33,127 | $3,333,000 | 1.80% |
| Biondo Investment Advisors, LLC | 104,120 | $10,475,000 | 1.80% |
| Tolleson Wealth Management, Inc. | 60,750 | $6,112,000 | 1.73% |
| Keel Point, LLC | 97,074 | $9,767,000 | 1.26% |